HC Wainwright Forecasts Weak Q4 Earnings for OPKO Health

Analysts lower earnings estimates for the biotechnology company

Mar. 5, 2026 at 2:26pm

Got story updates? Submit your updates here. ›

Stock analysts at HC Wainwright have dropped their Q4 2026 earnings per share (EPS) estimates for OPKO Health, a biotechnology company. HC Wainwright analyst Y. Chen now forecasts that OPKO Health will post earnings of ($0.08) per share for the quarter, down from their prior forecast of ($0.07). The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share.

Why it matters

OPKO Health's weaker than expected Q4 earnings forecast could impact investor confidence in the company and its stock performance. As a biotechnology firm, OPKO Health's financial results are closely watched by analysts and investors to gauge the company's progress and future prospects.

The details

In its most recent quarterly earnings report, OPKO Health posted earnings of ($0.04) per share, topping analysts' consensus estimates of ($0.07) per share. However, the company's revenue of $148.50 million for the quarter was down 19.1% on a year-over-year basis. OPKO Health has a negative net margin of 37.19% and a negative return on equity of 17.42%.

  • OPKO Health last announced its quarterly earnings data on Thursday, February 26th, 2026.
  • HC Wainwright analysts issued their note with the revised Q4 2026 earnings forecast on Monday, March 2nd, 2026.

The players

OPKO Health, Inc.

A diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development.

Y. Chen

An analyst at HC Wainwright who covers OPKO Health.

HC Wainwright

A stock research and investment banking firm that provides research coverage on OPKO Health.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

OPKO Health's weaker than expected Q4 earnings forecast highlights the challenges the biotechnology company is facing, including declining revenue and profitability. Investors will be closely watching the company's future financial performance and strategic initiatives to see if it can turn things around.